AU2015317329B2 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors - Google Patents
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors Download PDFInfo
- Publication number
- AU2015317329B2 AU2015317329B2 AU2015317329A AU2015317329A AU2015317329B2 AU 2015317329 B2 AU2015317329 B2 AU 2015317329B2 AU 2015317329 A AU2015317329 A AU 2015317329A AU 2015317329 A AU2015317329 A AU 2015317329A AU 2015317329 B2 AU2015317329 B2 AU 2015317329B2
- Authority
- AU
- Australia
- Prior art keywords
- oxo
- chloro
- methyl
- amino
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*)(C(C(N(*)C(C(N)=C)=CC)=O)=I)NC1=[U]C(C)=C(*)N(*)C1=O Chemical compound CC(*)(C(C(N(*)C(C(N)=C)=CC)=O)=I)NC1=[U]C(C)=C(*)N(*)C1=O 0.000 description 4
- BYBZTCCZRUAWLM-UHFFFAOYSA-N CC(C)(C)OC(Nc(cc1OCC2CC2)c(C=O)cc1Cl)=O Chemical compound CC(C)(C)OC(Nc(cc1OCC2CC2)c(C=O)cc1Cl)=O BYBZTCCZRUAWLM-UHFFFAOYSA-N 0.000 description 1
- NTMADQCRNMLNLX-XHNXRLJJSA-N CC(C)(C)[S@@](/N=C/c1nc(cc(cc2)Cl)c2nc1OC)=C Chemical compound CC(C)(C)[S@@](/N=C/c1nc(cc(cc2)Cl)c2nc1OC)=C NTMADQCRNMLNLX-XHNXRLJJSA-N 0.000 description 1
- JWJWGYAEABOLJI-UHFFFAOYSA-N CC(c(cc(cc(c(F)c1)Cl)c1n1)c1Cl)NS(C(C)(C)C)=O Chemical compound CC(c(cc(cc(c(F)c1)Cl)c1n1)c1Cl)NS(C(C)(C)C)=O JWJWGYAEABOLJI-UHFFFAOYSA-N 0.000 description 1
- LAYKQGIOKJHBBL-UHFFFAOYSA-N CCC(C(Nc1c2)=O)=Cc1cc(Cl)c2OC(C)C Chemical compound CCC(C(Nc1c2)=O)=Cc1cc(Cl)c2OC(C)C LAYKQGIOKJHBBL-UHFFFAOYSA-N 0.000 description 1
- KEGMQPZAHTVFLF-UHFFFAOYSA-N CCC1=Cc2cc(Cl)ccc2NC1=O Chemical compound CCC1=Cc2cc(Cl)ccc2NC1=O KEGMQPZAHTVFLF-UHFFFAOYSA-N 0.000 description 1
- UUSRDESYSIHKNV-UHFFFAOYSA-N CCN(C=CC=C1N)C1=O Chemical compound CCN(C=CC=C1N)C1=O UUSRDESYSIHKNV-UHFFFAOYSA-N 0.000 description 1
- VMUOXNQVBSAYQR-UHFFFAOYSA-N CN(C(C#N)=CC=C1F)C1=O Chemical compound CN(C(C#N)=CC=C1F)C1=O VMUOXNQVBSAYQR-UHFFFAOYSA-N 0.000 description 1
- CHCQKMBNHJJUGQ-UHFFFAOYSA-N COc(cc(c(C=C1C=O)c2)NC1=O)c2Cl Chemical compound COc(cc(c(C=C1C=O)c2)NC1=O)c2Cl CHCQKMBNHJJUGQ-UHFFFAOYSA-N 0.000 description 1
- TZKQLILAWIHUMT-VIFPVBQESA-N C[C@@H](C(C(Nc1c2)=O)=Cc1cc(Cl)c2F)NC1=CC=C(C#N)N(C)C1=O Chemical compound C[C@@H](C(C(Nc1c2)=O)=Cc1cc(Cl)c2F)NC1=CC=C(C#N)N(C)C1=O TZKQLILAWIHUMT-VIFPVBQESA-N 0.000 description 1
- XNAFIQOLGXHMGH-QMMMGPOBSA-N C[C@@H](C1=Cc2cc(C)ccc2NC1=O)N Chemical compound C[C@@H](C1=Cc2cc(C)ccc2NC1=O)N XNAFIQOLGXHMGH-QMMMGPOBSA-N 0.000 description 1
- ONPYRZSDSGLGKI-UHFFFAOYSA-N N#CC(NC1=O)=CC=C1F Chemical compound N#CC(NC1=O)=CC=C1F ONPYRZSDSGLGKI-UHFFFAOYSA-N 0.000 description 1
- ITOQFKSVNIQRLI-UHFFFAOYSA-N NCC1=Cc2cc(Cl)cc(F)c2NC1=O Chemical compound NCC1=Cc2cc(Cl)cc(F)c2NC1=O ITOQFKSVNIQRLI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019283765A AU2019283765B2 (en) | 2014-09-19 | 2019-12-16 | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| AU2021215141A AU2021215141B2 (en) | 2014-09-19 | 2021-08-10 | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053006P | 2014-09-19 | 2014-09-19 | |
| US62/053,006 | 2014-09-19 | ||
| US201562128089P | 2015-03-04 | 2015-03-04 | |
| US62/128,089 | 2015-03-04 | ||
| US201562150812P | 2015-04-21 | 2015-04-21 | |
| US62/150,812 | 2015-04-21 | ||
| PCT/US2015/051055 WO2016044789A1 (en) | 2014-09-19 | 2015-09-18 | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019283765A Division AU2019283765B2 (en) | 2014-09-19 | 2019-12-16 | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015317329A1 AU2015317329A1 (en) | 2017-04-27 |
| AU2015317329B2 true AU2015317329B2 (en) | 2019-10-31 |
Family
ID=54291606
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015317329A Active AU2015317329B2 (en) | 2014-09-19 | 2015-09-18 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| AU2019283765A Active AU2019283765B2 (en) | 2014-09-19 | 2019-12-16 | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| AU2021215141A Active AU2021215141B2 (en) | 2014-09-19 | 2021-08-10 | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019283765A Active AU2019283765B2 (en) | 2014-09-19 | 2019-12-16 | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| AU2021215141A Active AU2021215141B2 (en) | 2014-09-19 | 2021-08-10 | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Country Status (37)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6067226B2 (ja) | 2009-03-13 | 2017-01-25 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞増殖関連疾患のための方法および組成物 |
| CA2793835C (en) * | 2009-10-21 | 2021-07-20 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| RS57843B1 (sr) | 2014-02-06 | 2018-12-31 | Heptares Therapeutics Ltd | Biciklična aza jedinjenja kao agonisti muskarinskog receptora m1 |
| MX373789B (es) | 2014-09-19 | 2020-03-23 | Forma Therapeutics Inc | Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). |
| ES2706888T3 (es) | 2014-09-19 | 2019-04-01 | Forma Therapeutics Inc | Referencia cruzada a aplicaciones relacionadas |
| CN107001331A (zh) | 2014-09-19 | 2017-08-01 | 拜耳制药股份公司 | 作为bub1抑制剂的苄基取代的吲唑 |
| WO2016044781A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| ES2953347T3 (es) | 2014-09-19 | 2023-11-10 | Forma Therapeutics Inc | Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante |
| CN107428690B (zh) * | 2014-12-22 | 2021-04-13 | 美国政府健康及人类服务部 | 可用于治疗癌症的突变idh1抑制剂 |
| WO2016171755A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US10407419B2 (en) | 2015-04-21 | 2019-09-10 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| US11827616B2 (en) | 2017-05-04 | 2023-11-28 | Discovery Purchaser Corporation | Heterocyclic compounds as pesticides |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| WO2020232381A1 (en) | 2019-05-16 | 2020-11-19 | Forma Therapeutics, Inc. | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) |
| HUE061331T2 (hu) * | 2018-05-16 | 2023-06-28 | Forma Therapeutics Inc | Mutáns IDH-1 gátlása |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| LT3720442T (lt) | 2018-05-16 | 2023-04-25 | Forma Therapeutics, Inc. | Mutantinės idh-1 slopinimas |
| TW202104207A (zh) * | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| US11566013B1 (en) * | 2019-11-20 | 2023-01-31 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1) |
| CN112341389B (zh) * | 2020-10-27 | 2022-07-29 | 浙江工业大学 | 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用 |
| CN112321571B (zh) * | 2020-10-27 | 2022-06-03 | 浙江工业大学 | 2-呋喃-喹啉-4-甲酰胺类化合物及其应用 |
| CN115850240B (zh) * | 2022-12-28 | 2023-09-19 | 北京康立生医药技术开发有限公司 | 一种治疗急性髓系白血病药物奥卢他西尼的合成方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006054912A1 (fr) * | 2004-11-18 | 2006-05-26 | Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' | Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base |
| WO2008010964A1 (en) * | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| WO2011072174A1 (en) * | 2009-12-09 | 2011-06-16 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| WO2013102431A1 (en) * | 2012-01-06 | 2013-07-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2014141153A1 (en) * | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99731A0 (en) | 1990-10-18 | 1992-08-18 | Merck & Co Inc | Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US20030105124A1 (en) | 2000-04-27 | 2003-06-05 | Susan Beth Sobolov-Jaynes | Substituted benzolactam compounds |
| JP2005532368A (ja) | 2002-06-12 | 2005-10-27 | アボット・ラボラトリーズ | メラニン濃縮ホルモン受容体の拮抗薬 |
| WO2004043936A1 (ja) | 2002-11-14 | 2004-05-27 | Kyowa Hakko Kogyo Co., Ltd. | Ｐｌｋ阻害剤 |
| RU2284325C2 (ru) | 2003-12-17 | 2006-09-27 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе |
| US7956060B2 (en) | 2004-03-30 | 2011-06-07 | Kyowa Hakko Kirin Co., Ltd. | Pyrimidine derivative compound |
| TW200803855A (en) | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
| JP2010043004A (ja) | 2006-12-06 | 2010-02-25 | Dainippon Sumitomo Pharma Co Ltd | 新規２環性複素環化合物 |
| CA2684968C (en) | 2007-04-30 | 2015-07-07 | Prometic Biosciences Inc. | Compounds, compositions containing such compounds, and methods of treatment of cancer and autoimmune diseases using such compounds |
| EP2440050A4 (en) | 2009-06-08 | 2013-04-03 | California Capital Equity Llc | TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION |
| WO2012006104A2 (en) | 2010-06-28 | 2012-01-12 | Academia Sinica, Taiwan | Compounds and methods for treating tuberculosis infection |
| CN102558049B (zh) | 2010-12-17 | 2015-02-04 | 中国科学院上海药物研究所 | 一类双香豆素类化合物及其制备方法和用途 |
| US20120184548A1 (en) | 2011-01-19 | 2012-07-19 | Romyr Dominique | Carboxylic acid aryl amides |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN103814020B (zh) * | 2011-06-17 | 2017-07-14 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| GEP20166432B (en) | 2011-09-27 | 2016-02-10 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| KR102097343B1 (ko) | 2011-12-21 | 2020-04-07 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | RAL GTPases를 타겟으로 하는 항암용 화합물 및 이의 사용방법 |
| WO2015003146A1 (en) | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| JP6534675B2 (ja) | 2014-02-11 | 2019-06-26 | バイエル・ファルマ・アクティエンゲゼルシャフト | ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン |
| ES2706888T3 (es) | 2014-09-19 | 2019-04-01 | Forma Therapeutics Inc | Referencia cruzada a aplicaciones relacionadas |
| WO2016044781A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| MX373789B (es) | 2014-09-19 | 2020-03-23 | Forma Therapeutics Inc | Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). |
| ES2953347T3 (es) * | 2014-09-19 | 2023-11-10 | Forma Therapeutics Inc | Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante |
| CN107428690B (zh) | 2014-12-22 | 2021-04-13 | 美国政府健康及人类服务部 | 可用于治疗癌症的突变idh1抑制剂 |
| GB2533925A (en) | 2014-12-31 | 2016-07-13 | Univ Bath | Antimicrobial compounds, compositions and methods |
| US10407419B2 (en) | 2015-04-21 | 2019-09-10 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| WO2016171755A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| EP3328866B1 (en) | 2015-07-27 | 2019-10-30 | Eli Lilly and Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
| KR20180114202A (ko) | 2016-02-26 | 2018-10-17 | 아지오스 파마슈티컬스 아이엔씨. | 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제 |
| US10696665B2 (en) | 2016-06-06 | 2020-06-30 | Eli Lilly And Company | Mutant IDH1 inhibitors |
| JP6987798B2 (ja) | 2016-06-22 | 2022-01-05 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 癌の治療に変異体ｉｄｈ１阻害剤として有用なチアゾール誘導体 |
| ES2941631T3 (es) | 2016-12-16 | 2023-05-24 | Lilly Co Eli | Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes |
-
2015
- 2015-09-18 ES ES20157755T patent/ES2953347T3/es active Active
- 2015-09-18 EA EA201790657A patent/EA034336B1/ru unknown
- 2015-09-18 MX MX2017003404A patent/MX2017003404A/es active IP Right Grant
- 2015-09-18 MA MA040481A patent/MA40481A/fr unknown
- 2015-09-18 PT PT201577558T patent/PT3733662T/pt unknown
- 2015-09-18 RS RS20200418A patent/RS60140B1/sr unknown
- 2015-09-18 MA MA053352A patent/MA53352A/fr unknown
- 2015-09-18 IL IL292608A patent/IL292608B2/en unknown
- 2015-09-18 JP JP2017515059A patent/JP6648115B2/ja active Active
- 2015-09-18 SM SM20190018T patent/SMT201900018T1/it unknown
- 2015-09-18 CN CN202311265288.0A patent/CN117695280A/zh active Pending
- 2015-09-18 HU HUE20157755A patent/HUE062424T2/hu unknown
- 2015-09-18 KR KR1020177010585A patent/KR102209667B1/ko active Active
- 2015-09-18 NZ NZ73037315A patent/NZ730373A/en unknown
- 2015-09-18 CN CN202010391529.6A patent/CN111909130B/zh active Active
- 2015-09-18 FI FIEP20157755.8T patent/FI3733662T3/fi active
- 2015-09-18 PL PL15778433T patent/PL3194376T3/pl unknown
- 2015-09-18 EP EP15778433.1A patent/EP3194376B1/en active Active
- 2015-09-18 DK DK18198969.0T patent/DK3447050T3/da active
- 2015-09-18 ES ES15778433T patent/ES2704897T3/es active Active
- 2015-09-18 BR BR112017005238-5A patent/BR112017005238B1/pt active IP Right Grant
- 2015-09-18 PL PL18198969T patent/PL3447050T3/pl unknown
- 2015-09-18 PL PL20157755.8T patent/PL3733662T3/pl unknown
- 2015-09-18 HU HUE15778433A patent/HUE041460T2/hu unknown
- 2015-09-18 MY MYPI2017700895A patent/MY176250A/en unknown
- 2015-09-18 CA CA2961817A patent/CA2961817C/en active Active
- 2015-09-18 PT PT15778433T patent/PT3194376T/pt unknown
- 2015-09-18 DK DK15778433.1T patent/DK3194376T3/en active
- 2015-09-18 RS RS20181586A patent/RS58184B1/sr unknown
- 2015-09-18 ME MEP-2020-78A patent/ME03776B/me unknown
- 2015-09-18 MY MYPI2020001463A patent/MY197533A/en unknown
- 2015-09-18 TW TW104131044A patent/TWI686390B/zh active
- 2015-09-18 SI SI201530537T patent/SI3194376T1/sl unknown
- 2015-09-18 ES ES18198969T patent/ES2790640T3/es active Active
- 2015-09-18 LT LTEP18198969.0T patent/LT3447050T/lt unknown
- 2015-09-18 PE PE2017000471A patent/PE20171056A1/es unknown
- 2015-09-18 CN CN201580050441.5A patent/CN107001328B/zh active Active
- 2015-09-18 MX MX2019013203A patent/MX385512B/es unknown
- 2015-09-18 LT LTEP15778433.1T patent/LT3194376T/lt unknown
- 2015-09-18 EP EP20157755.8A patent/EP3733662B1/en active Active
- 2015-09-18 EP EP18198969.0A patent/EP3447050B1/en active Active
- 2015-09-18 EP EP23176702.1A patent/EP4257131A3/en active Pending
- 2015-09-18 WO PCT/US2015/051055 patent/WO2016044789A1/en not_active Ceased
- 2015-09-18 SM SM20200212T patent/SMT202000212T1/it unknown
- 2015-09-18 SG SG11201702194SA patent/SG11201702194SA/en unknown
- 2015-09-18 US US14/858,167 patent/US9834539B2/en active Active
- 2015-09-18 PH PH1/2017/500517A patent/PH12017500517B1/en unknown
- 2015-09-18 PT PT181989690T patent/PT3447050T/pt unknown
- 2015-09-18 SI SI201531117T patent/SI3447050T1/sl unknown
- 2015-09-18 AU AU2015317329A patent/AU2015317329B2/en active Active
-
2017
- 2017-03-07 US US15/452,256 patent/US20170174658A1/en not_active Abandoned
- 2017-03-14 IL IL251163A patent/IL251163B/en active IP Right Grant
- 2017-03-17 CL CL2017000658A patent/CL2017000658A1/es unknown
- 2017-03-19 SA SA517381129A patent/SA517381129B1/ar unknown
- 2017-03-27 ZA ZA2017/02127A patent/ZA201702127B/en unknown
- 2017-04-03 CO CONC2017/0003241A patent/CO2017003241A2/es unknown
- 2017-04-13 EC ECIEPI201722933A patent/ECSP17022933A/es unknown
-
2018
- 2018-04-27 US US15/964,844 patent/US10414752B2/en active Active
-
2019
- 2019-01-21 CY CY20191100075T patent/CY1121149T1/el unknown
- 2019-03-01 US US16/290,240 patent/US10550098B2/en active Active
- 2019-04-17 ZA ZA2019/02446A patent/ZA201902446B/en unknown
- 2019-12-12 US US16/712,951 patent/US10889567B2/en active Active
- 2019-12-16 AU AU2019283765A patent/AU2019283765B2/en active Active
-
2020
- 2020-04-24 HR HRP20200666TT patent/HRP20200666T1/hr unknown
- 2020-05-04 CY CY20201100407T patent/CY1122865T1/el unknown
- 2020-11-23 US US17/101,018 patent/US11498913B2/en active Active
-
2021
- 2021-04-18 IL IL282363A patent/IL282363B/en unknown
- 2021-08-10 AU AU2021215141A patent/AU2021215141B2/en active Active
-
2022
- 2022-11-09 US US17/984,069 patent/US20230125739A1/en not_active Abandoned
-
2023
- 2023-04-14 ZA ZA2023/04409A patent/ZA202304409B/en unknown
- 2023-11-09 US US18/506,060 patent/US12275715B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006054912A1 (fr) * | 2004-11-18 | 2006-05-26 | Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' | Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base |
| WO2008010964A1 (en) * | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| WO2011072174A1 (en) * | 2009-12-09 | 2011-06-16 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| WO2013102431A1 (en) * | 2012-01-06 | 2013-07-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2014141153A1 (en) * | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015317329B2 (en) | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| EP3194375B1 (en) | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| AU2015317327B9 (en) | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| HK40102356A (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| HK40033589A (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| HK40033589B (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| HK40002980A (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| HK40002980B (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| HK1241376A1 (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| HK1241376B (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ASHWELL, SUSAN; CAMPBELL, ANN-MARIE; CARAVELLA, JUSTIN ANDREW; DIEBOLD, R. BRUCE; ERICSSON, ANNA; GUSTAFSON, GARY; LANCIA, JR., DAVID R.; LIN, JIAN; LU, WEI AND WANG, ZHONGGUO |
|
| FGA | Letters patent sealed or granted (standard patent) |